Union Commerce and Industry Minister Piyush Goyal announced on June 8 that India's pharmaceutical industry, currently valued at around $60 billion, is on track to nearly double in the next five years. He emphasized the importance of transitioning from a generics manufacturing hub to a global innovation center in pharmaceuticals. Goyal highlighted that this shift would not compromise India's existing strengths in affordable generic medicines, stating the goal is to enhance innovative products while maintaining the benefits of generics for patients worldwide. He noted that India now has the largest number of US FDA-approved pharmaceutical plants, reinforcing its position as a trusted supplier to regulated markets like the United States and Europe. Goyal also pointed out the advantages of India's expanding trade network, with several free trade agreements (FTAs) offering near-zero tariff access to various partner markets. He urged global pharmaceutical companies to increase their operations in India, citing the vast domestic market of 1.4 billion people, a growing middle class, and resilient economic growth despite global geopolitical tensions. Goyal remarked that India achieved a growth rate of 7.7% in FY26, even amid challenges such as tariffs imposed by the US and ongoing conflicts in Ukraine and West Asia.